NARTH founder Joseph Nicolosi, arguably the father of modern reparative therapy, has retracted his claim that a patient was able to change his sexual orientation through an SSRI.
In 2009, Dr Nicolosi said his client had made no progress in eight years of therapy, but after a course of Lexapro, a brand of the antidepressant escitalopram, “he discovered that he had no more sexual attractions to men.” Although his claim failed to find a publisher, it didn’t stop NARTH using it as evidence in its 2009 ground-breaking, peer-reviewed study, the notorious publication that turned out not to be ground-breaking, peer-reviewed or even a study — it was a mere (very selective) literature review, published by NARTH and reviewed internally.
Nicolosi has now said the evidence doesn’t support Lexapro as a gay cure. Writes Dr Warren Throckmorton, who reported this story:
Instead of noting that the case reported was only one success out of four tries, the authors [of the NARTH paper] only noted the one case which appeared to be a success at the time. Now, according to Dr. Nicolosi, Lexapro has not lived up to that claim.
This report can be added to others where significant questions have been raised (e.g., the Bieber study, the Kaye study, the work of Masters and Johnson, the Pattison and Pattison research).